MMSI - AngioDynamics - Undervalued Gem In Med Tech: Analyst Eyes Stellar Growth With A 'Buy' Stance | Benzinga
H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ: ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.
AngioDynamics currently generates over 80% of its revenue from the U.S. and the rest from international markets. The analyst notes substantial room for further growth given the company's focus on the high-growth Med Tech segment with differentiated products.
Analysts Yi Chen and Raghuram Selvaraju have initiated the coverage with a Buy rating and a price target of $19 and say the current valuation ...